Sent by Cliff (he was having trouble posting) - thanks!

**********************************************************************


Israeli biopharmaceutical start-up, Vascular Biogenics Ltd., has
developed a new genetic treatment, GT-111, which can cut off the
oxygen supply to cancerous tumors causing them to shrink
dramatically, or even disappear completely, without any negative side-
effects to the patient.

The treatment is based on a genetic charge that destroys the
endothelial cells that build the blood vessels and supply oxygen to a
cancerous tumor and its metastases. Without oxygen the tumor begins
to shrink in size. Unlike current treatments that are based on
killing the tumor's cells through chemotherapy, radiation and hormone
treatments, and cause severe side effect, VBL's treatment has no side
effects because it is not targeted at carcinogenic cells, but at the
blood vessels that allow the metastases to grow. The treatment has
already been tested successfully in animals and is likely to start
clinical trials by the end of this year.

http://www.cgp.be/biotech/biotech2e.html